Giovanni Maria Fadda

Dr. Giovanni Maria Fadda


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MRManuela Rodio
Manuela Rodio
MTMatilde Tettamanzi
Matilde Tettamanzi
ETEmilio Trignano
Emilio Trignano
SRSilvia Rampazzo
Silvia Rampazzo
PSPietro Luciano Serra
Pietro Luciano Serra
CRCorrado Rubino
Corrado Rubino
Background: Scalp-associated cutaneous squamous cell carcinoma (cSCC) presents formidable treatment challenges, especially when it leads to full-thickness defects involving bone. Aggressive or recurring cases often demand a multidisciplinary approach. Leveraging our surgical experience and a literature review, we introduce a therapeutic algorithm to guide the selection of reconstruction methods, particularly for locally advanced lesions, furthermore showing the synergy between surgery and other therapies for comprehensive, multidisciplinary disease management. Methods: Our algorithm stems from a retrospective analysis of 202 patients undergoing scalp cSCC resection and reconstruction over a 7-year period, encompassing 243 malignancies. After rigorous risk assessment and documentation of surgical procedures, reconstruction methods were therefore related to malignancy extent, depth, and individual clinical status. Results: The documented reconstructions included 76 primary closures, 115 skin grafts, 7 dermal substitute reconstructions, 33 local flaps, 1 locoregional flap, and 1 microsurgical free flap. Patients unsuitable for surgery received radiotherapy or immunotherapy after histological confirmation. Precise analysis of tumor characteristics in terms of infiltration extent and depth guided the selection of appropriate reconstruction and treatment strategies Combining these insights with an extensive literature review enabled us to formulate our algorithm for managing scalp cSCCs. Conclusions: Effectively addressing scalp cSCC, especially in locally advanced or recurrent cases, demands a systematic approach integrating surgery, radiotherapy, and immunotherapy. Our multidisciplinary team’s decision-making algorithm improved patient outcomes by offering a broader spectrum of therapeutic options that can synergistically achieve optimal results.

26 August 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
CPCarlo Putzu
Carlo Putzu
RSRiccardo Serra
Riccardo Serra
RCRachele Campus
Rachele Campus
GFGiovanni Maria Fadda
Giovanni Maria Fadda
CSClaudio Sini
Claudio Sini
Panagiotis PaliogiannisPanagiotis Paliogiannis
Panagiotis Paliogiannis
Background: The aim of the study was to investigate a series of complete blood cell count-based biomarkers of systemic inflammation as predictors of clinical outcomes in patients who underwent first-line chemoimmunotherapy for advanced NSCLC. Methods: Consecutive patients with pathologically diagnosed stage III/IV NSCLC and PD-L1 < 50% who underwent first-line chemoimmunotherapy were retrospectively enrolled. The clinical outcomes used for biomarker evaluation were Objective Response Rate (ORR) and Overall Survival (OS). Results: Non-responders had significantly higher values of neutrophil to lymphocyte ratio (NLR, median: 5.36; IQR: 2.78–10.82 vs. 3.31; IQR: 2.15–4.12, p = 0.019), neutrophil to monocyte ratio (NMR, median: 14.00; IQR: 8.82–21.20 vs. 9.20; IQR: 7.45–11.20, p = 0.013), and systemic inflammation index (SII, median: 1395; IQR: 929–3334 vs. 945; IQR: 552–1373, p = 0.025), but only NLR and NMR remained independently associated with clinical response in multivariate logistic regression. In the univariate analysis, white blood cells (OR:1.2202; 95% CI: 1.0339–1.4400, p = 0.019), neutrophils (OR:1.2916; 95% CI: 1.0692–1.5604, p = 0.008), NLR (OR:1.3601: 95% CI: 1.0949–1.6896, p = 0.005) and NMR (OR:1.2159; 95% CI: 1.00396–1.4221, p = 0.015) were significantly associated with survival; Cox regression models confirmed that neutrophils, NLR, and MLR were independently associated with survival; NLR, at a cut-off value of 4.0, showed the better AUC (0.749) in predicting OS. Conclusions: Baseline complete blood cell count biomarkers, especially the NLR, can predict clinical outcomes in patients with advanced NSCLC treated with first-line chemoimmunotherapy.

22 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MCMaria Colombino
Maria Colombino
Giuseppe PalmieriGiuseppe Palmieri
Giuseppe Palmieri
MRManuela Rodio
Manuela Rodio
MTMatilde Tettamanzi
Matilde Tettamanzi
SRSilvia Rampazzo
Silvia Rampazzo
CRCorrado Rubino
Corrado Rubino
Cutaneous squamous cell carcinoma is a prevalent malignancy with a rising incidence and a notably high mutational load. Exploring the genetic nuances of cSCC and investigating molecular approaches stands as a potential avenue for improving outcomes in high-risk patients. This retrospective case-control study involved two cohorts, one of 14 patients (the “discovery cohort”) and the other of 12 patients (the “validation cohort”), with cSCC located in the head/neck anatomical region and diagnosed at the pT2 stage. Overall, cases developed early local relapses of the disease, whereas controls never relapsed during the entire follow-up period. A next-generation sequencing (NGS) approach conducted on histological samples revealed that TP53 and CDKN2A were the most frequently mutated genes in our series. No specific mutations were identified as potential prognostic or therapeutic targets. Controls exhibited a tendency toward a higher mutational rate compared to cases. It is possible that an increased number of mutations could prompt the cSCC to expose more antigens, becoming more immunogenic and facilitating recognition by the immune system. This could enhance and sustain the immunological response, potentially preventing future recurrences.

8 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMaria Colombino
Maria Colombino
Giuseppe PalmieriGiuseppe Palmieri
Giuseppe Palmieri
MRManuela Rodio
Manuela Rodio
MTMatilde Tettamanzi
Matilde Tettamanzi
SRSilvia Rampazzo
Silvia Rampazzo
CRCorrado Rubino
Corrado Rubino
Cutaneous squamous cell carcinoma is a prevalent malignancy with a rising incidence and notably high mutational load. Exploring the genetic nuances of cSCC and investigating molecular approaches stands as a potential avenue for improving outcome in high-risk patients. This retrospective case-control study involved two cohorts of 14 patients (“discovery cohort”) and 12 patients (“validation cohort”) with cSCC located in head-neck anatomical district and diagnosed at pT2 stage. Overall, cases developed early local relapse of the disease whereas controls never re-lapsed during the entire follow-up period. Next generation sequencing (NGS) approach conducted on histological samples revealed that TP53 and CDKN2A were the most frequently mutated genes in our series. No specific mutation was identified as potential prognostic or therapeutic targets. Controls exhibited a tendency toward a higher mutational rate compared to cases. It is possible that an increased number of mutations could prompt the cSCC to expose more antigens, becoming more immunogenic and facilitating the recognition by the immune system. This could enhance and sustain immunological response, potentially preventing future recurrences.

18 October 2023
Verified
Book Chapter
Closed access
PDF file
APAntonio Piras
Antonio Piras
DRDavide Rizzo
Davide Rizzo
EDEmilia Degni
Emilia Degni
CCClaudia Crescio
Claudia Crescio
ARAlessia Re
Alessia Re
APAntonio Pazzola
Antonio Pazzola

18 October 2023
Verified
Book Chapter
Closed access
PDF file
TPTropiano Paolo
Tropiano Paolo
FPFois Paolo
Fois Paolo
MAMelis Andrea
Melis Andrea
LLLaura Maria De Luca
Laura Maria De Luca
FMFrancesco Miccichè
Francesco Miccichè
DRDavide Rizzo
Davide Rizzo